Effect of Guanxinning Tablets on the Numerical Levels of Pentraxin-3 and Related Blood Cell Analysis in Patients with Coronary Heart Disease and Diastolic Heart Failure

OBJECTIVE To observe the effect of Guanxinning tablets on the numerical levels of pentraxin-3(PTX-3) and related blood cell analysis in patients with coronary heart disease and diastolic heart failure(DHF). METHODS Eighty patients with blood stasis syndrome of coronary heart disease and DHF who were treated in Lishui Hospital of Traditional Chinese Medicine from November 2018 to November 2019 were selected as the research objects. They were divided into control group and treatment group by a random number table method, each with 40 cases. The control group was treated with western medicine, the treatment group was treated with Guanxinning tablets on the basis of the control group with continuous treatment for 4 weeks. TCM syndrome scores, clinical efficacy, the the ratio of early diastolic mitral inflow velocity to early diastolic velocity of the mitral annulus(E/E'), the numerical levels of N-terminal pro-brain natriuretic peptide(NT-proBNP), PTX-3 and related blood cell analysis such as the red blood cell distribution width(RDW), platelet to lymphocyte ratio(PLR), monocyte to lymphocyte ratio(MLR), neutrophil to lymphocyte ratio(NLR) were observed in the two groups, so as to evaluate the therapeutic effect of patients with blood stasis syndrome of coronary heart disease and DHF. RESULTS After treatment, the total effective rate of the treatment group was 90.0%, which was significantly higher than 75.93% in the control group(P<0.05). Before treatment, TCM syndrome scores, E/E', NT-proBNP, PTX-3, RDW, PLR, MLR and NLR were not statistically different in the two groups. After treatment, TCM syndrome scores, E/E', NT-proBNP, PTX3, RDW, PLR, MLR and NLR were significantly lower in the two groups compared with before treatment(P<0.05), and the indexes in treatment group were significantly lower than those in the control group(P<0.05). There were no adverse reactions in both groups after treatment. CONCLUSION Guanxinning tablets can effectively improve clinical symptoms of patients with coronary heart disease and DHF, can effectively reduce the TCM syndrome scores, E/E', NT-proBNP, PTX-3 and related blood cell analysis value level, and enhance the clinical effect.